Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Conditions:   Head and Neck Cancer;   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: Ibrutinib 560mg PO daily;   Drug: Ibrutinib 560mg PO daily (Imbruvica);   Drug: Cetuximab;   Drug: Nivolumab
Sponsors:   University of California, San Diego;   Pharmacyclics LLC.
Not yet recruiting

https://ift.tt/2P3Ac3N